What the Best Biotech Brands Get Right
Toward a theory of the Brave Biotech Brand
This is a deep look at the intersection of brand, economics, and biotech, folks. Buckle up.
So, last week, in Trust, Story, and the Future of Biotech, I wrote about the deeper human side of clarity and communication in science, how trust becomes the substrate for everything else.
The week before that, in Why Brand Is Becoming a Biotech Growth Engine, I argued that brand is not a cosmetic layer but a structural asset in an industry built on intangibles.
Today, I want to push this further.
If clarity is the engine of trust, and trust is the engine of traction, then value is the engine of meaning.
And biotech has a value problem.
Not because it fails to create value. Biotech creates more value than almost any industry on earth, but our economic language is too small to describe what that value actually is.
This essay is an attempt to redraw that map.
The Economics of Value Creation in Biotech
I have a real love for: data + humans = economics. And if you study economics long enough, you eventually notice a repeating puzzle: Who decides what counts as value? In traditional markets, value is defined by what the system can easily measure:
- revenues
- margins
- multiples
- quarterly guidance
But biotech creates value in a fundamentally different way:
The unit of value is not the product.
It is the reduction of future harm.
And markets are not set up to price that correctly.
Biotech produces:
- longer lives
- healthier populations
- fewer catastrophic events
- reduced lifetime disease burden
- scientific spillovers
- intergenerational wellbeing
- ecosystem resilience
These are real, measurable, life-altering forms of value. But because they are intangible, long-horizon, and distributed, they are systematically mispriced. And they are often invisible. This mispricing is not a footnote in biotech. It is the central problem that everything else orbits. Whew, that feels good to say out loud! Let’s examine its mechanics.
Value Creation vs. Value Extraction
Economist Mariana Mazzucato draws a critical distinction:
- Value creation = generating new capabilities, health, knowledge, wellbeing
- Value extraction = capturing income without equivalent contribution
Most industries function with both. Biotech magnifies the stakes. A therapy that prevents disease is value creation. A pricing strategy that exploits vulnerability is value extraction. A platform that accelerates innovation is value creation. An IP moat that blocks foundational tools is value extraction. See a pattern emerging? These are not semantic differences. They define whether a company advances the field, or merely profits from it.
Information asymmetry is when one party in a relationship or transaction has far more knowledge than the other, creating an imbalance of power, understanding, and decision-making.
Information Asymmetry and the Economics of Trust
Biotech exists in an extreme information-asymmetry environment:
- complex science
- opaque risks
- probabilistic outcomes
- specialized language
- long biological feedback loops
In such conditions:
Trust is not a soft asset.
Trust is an economic input.
High-trust companies experience:
- reduced perceived risk
- improved regulatory relationships
- faster comprehension
- smoother partnerships
- steadier valuations
Low-trust companies face the inverse. Brand (done with integrity) is the mechanism that makes trust legible.
Knowledge as a Public Good
Economists like Kenneth Arrow have long argued that knowledge is:
- non-rivalrous
- cumulative
- spillover-rich
- underfunded by markets
Biotech generates enormous positive externalities:
- shared methods
- investigative tools
- mechanistic insights
- discovery pathways
- epidemiological models
- talent development
- public-health capacity
This is foundational value, yet rarely captured in company financials. Organizations that invest in public goods are often undervalued because markets cannot price what they produce.
Stakeholder Value and Long-Term Horizons
Biotech unfolds over decades. Its work shapes:
- patients
- families
- clinicians
- payers
- regulators
- communities
- ecosystems
- future generations
This is stakeholder capitalism in its densest form. And yet the financial system rewards short-term indicators more than long-term societal benefit. Brave companies find ways to resist this gravitational pull.
Stakeholder capitalism is an economic model where a company is accountable not just to shareholders, but to everyone affected by its decisions—employees, customers, communities, partners, regulators, and the environment.
Intangible Assets and the Mispricing of Biotech
Most of the value created by biotech is intangible:
- trust
- credibility
- scientific reputation
- narrative coherence
- organizational clarity
- brand meaning
- institutional memory
Empirical studies across industries show intangibles now make up 90%+ of market capitalization. Yet biotech still behaves as if:
- science speaks for itself
- clarity is optional
- communication is secondary
- design is decorative
- narrative is marketing
- trust is a downstream function
This is why the industry systematically misprices itself. If anyone feels like building an AI tool to fix this, I’d love to help start that company!
Brand, narrative, design (far from superficial) are the tools that make intangible value visible, legible, and compounding.
A brave biotech brand understands this. A fragile one does not.
The Biotech Value Model: Harm, Time, Trust
Biotech creates value in a fundamentally different way than most industries. Most sectors create value by producing:
- goods
- services
- efficiencies
- convenience
- digital scale
Biotech creates value by doing something stranger. It reduces future harm. Not metaphorically. Literally. For us math nerds out there, it alters the probability distribution of suffering. This is a radically different value model than the one used in classical economics, and something I repeatedly ran into during my studies at university.
Traditional markets price:
- units sold
- margins
- demand curves
- present consumption
- near-term utilities
Biotech produces:
- future health
- reduced disease burden
- extended life-years
- decreased system strain
- positive scientific spillovers
- new infrastructure for discovery
- population-level wellbeing
- intergenerational externalities
This creates three economic problems:
1. Markets cannot easily price non-events.
Absence is not monetizable (at least yet). A disease prevented does not appear in revenue models. A future hospitalization avoided does not show up as a balance sheet gain. This means biotech’s most meaningful contributions are structurally underpriced.
2. Value is produced long before it is captured.
A discovery made today may not “pay out” for:
- 10 years
- 20 years
- or ever
But it still creates scientific, educational, ecosystem, and methodological value today. Capital markets are not built for this time horizon.
3. Most biotech value is intangible, therefore invisible.
Trust.
Understanding.
Reputation.
Narrative coherence.
Scientific legitimacy.
Ecosystem contribution.
These are not optional. They are the assets biotech actually runs on. Yet because they are intangible, they are consistently under-invested in.
Which is why biotech ends up mispriced, both economically and culturally.
A groundbreaking therapy may be undervalued because its benefits accrue over decades. A company that overclaims may be overvalued because it produces attractive short-term signals. A platform that produces open scientific spillovers may be structurally undervalued because markets do not reward shared benefit. A company that takes a long-term, ethical, ecosystem-centered approach may grow more slowly in the short term, even though it is creating far more real value. This is the economic root of my “Brave Brand” argument:
Biotech is not simply miscommunicated.
Biotech is mispriced.
And because it is mispriced, founders must design their own systems for understanding, trust, and value expression, or they are swallowed by the distortions of the market. This is where brand becomes economic infrastructure. This is also where the brave companies distinguish themselves.
Before going any further, we need to look at real companies. Ideas only matter when they show up in the wild. If bravery in biotech is about creating value the market cannot price, then the best examples are the ones already doing it. The following five organizations show what this looks like in practice. They approach science, design, trust, and value in ways that run against the grain. And they reveal the patterns that define a brave biotech brand.
Let’s begin.
ARCADIA SCIENCE
Open Knowledge as Economic Infrastructure
Arcadia Science is one of the most intellectually significant and economically subversive companies in modern biotechnology. Not because of a single therapeutic breakthrough or platform innovation, but because it is attempting to redesign the underlying machinery of scientific progress itself. And it is easy to miss how radical their work is.
To understand Arcadia, we must understand the problem it is responding to.
I. The Origin Problem: Scientific Publishing as a Bottleneck
To grasp the importance of Arcadia, it helps to recall the original sin of scientific publishing:
Publishing emerged to distribute knowledge; it evolved to distribute prestige.
Over time, journals became:
- gatekeepers
- status allocators
- impact-score arbiters
- career advancement machines
As a consequence:
- science slowed
- incentives distorted
- methods became opaque
- negative results disappeared
- early findings were buried
- reproducibility plummeted
- costs of participation increased
- public understanding eroded
This was not a communications problem. It was an economic problem. The science economy became structured around scarcity, secrecy, and credentialing, rather than utility, speed, and contribution. Arcadia was founded as a response to this misalignment, and I love them for that.
II. Founding Logic: Knowledge as a Fluid, Not a Commodity
Arcadia was co-founded by scientists and thinkers frustrated with the stagnation created by prestige publishing. Their thesis was simple, bold, and economically profound:
“If you redesign the flow of knowledge, you redesign the speed of discovery.”
This founding logic draws implicitly from:
- Arrow’s information economics (knowledge as a public good)
- Nelson & Winter’s evolutionary theory of firms (innovation emerges from variation + selection)
- Open-source software models (iteration > perfection)
- Lean R&D thinking (reduce cycle times, increase surface area for learning)
Arcadia’s founders looked at biology not as a discipline, but as an information system.
A system clogged by outdated incentives.
And so they asked:
What if the publication layer itself was redesigned?
Not as “open access.”
Not as “preprint culture.”
But as an entirely new epistemic and economic model for scientific production.
III. Arcadia’s Model: Publishing as the Core R&D Engine
Arcadia does not treat publishing as the output of science.
They treat publishing as the engine of science.
Their “pubs” work like modular, living documents:
- fast
- iterative
- richly annotated
- designed for comprehension
- optimized for reuse
- openly accessible
- transparent about uncertainty
- supportive of methodological rigour
- designed to welcome interdisciplinary readers
This is the opposite of traditional journals, which are:
- slow
- formal
- gatekept
- prestige-driven
- incentivized toward grand narratives
- formatted to signal authority rather than clarity
Arcadia’s model has three key innovations.
A. Epistemic Modularity
Instead of waiting until a narrative is “complete,” Arcadia publishes:
- fragments
- observations
- failed experiments
- partial results
- methodological notes
- early hypotheses
This accelerates the variation → selection → iteration cycle that evolutionary economists identify as the driver of innovation.
Arcadia increases the resolution and frequency of scientific learning.
B. Designed Comprehensibility (Design as Epistemology)
Arcadia’s documents are designed like:
- product documentation
- modular guides
- annotated code
- interactive methods
Design does not sit on top of knowledge.
Design shapes the knowledge itself.
This is “design as leadership” (Bruce Mau): design determines how something is understood, and thus what becomes possible.
Arcadia’s design choices:
- reduce cognitive load
- improve replication probability
- democratize methodological knowledge
- eliminate prestige signaling
- create porous boundaries between disciplines
- make scientific uncertainty legible
This is design functioning as:
- an economic accelerant
- an epistemic scaffold
- an ethical stance
C. Knowledge Liquidity as a Value Proposition
Arcadia treats knowledge like a fluid that must move freely to do its work. Knowledge liquidity creates:
- faster cumulative progress
- fewer duplicated efforts
- more interdisciplinary connection
- broader downstream innovation
- reduced time-to-insight
- higher overall productivity of the ecosystem
This is a massive economic contribution, and mostly unpriced.
Arcadia does not capture the value. They create it. This is bravery.
IV. Economic Theory in Application
Let’s ground Arcadia’s approach in concrete economic frameworks.
1. Information Asymmetry Reduction (Akerlof, Stiglitz)
Arcadia reduces the asymmetry between:
- experts vs early-career scientists
- elite institutions vs underfunded labs
- insiders vs external innovators
- native-English-speaking researchers vs global community
Reduction of asymmetry increases overall market efficiency.
2. Innovation Spillovers (Arrow, Romer)
Arcadia publishes work before capture, leading to:
- positive spillovers
- increased innovation in adjacent fields
- more rapid methodological diffusion
- downstream applications beyond their control
This is classic unpriced externality creation, the good kind.
3. Evolutionary Economics (Nelson & Winter)
Innovation emerges from:
- variation (more experiments)
- selection (feedback)
- retention (publication)
Arcadia accelerates all three.
4. Public-Goods Production (Ostrom)
Arcadia functions like:
- a knowledge steward
- a methodological commons manager
- a facilitator of shared resource governance
This is a governance innovation, not just a communications innovation.
V. Ethical and Societal Implications
Arcadia’s model:
- decentralizes scientific power
- democratizes access
- increases reproducibility
- reduces incentives for scientific fraud
- enhances global participation
- creates transparency where opacity was incentivized
Arcadia reduces epistemic inequality.
This is an ethical stance embedded into an operational model.
VI. Tensions, Risks, and Limitations
Arcadia is brave, but bravery has friction:
- slow capital adoption (because value creation > capture)
- skepticism from traditional academia
- cultural resistance to transparency
- the absence of prestige signals may harm early-career scientists in traditional systems
- publication norms are slow to change
But these tensions are signs of a transition, not failures.
VII. Why Arcadia Is a Brave Biotech Brand
Arcadia is “brave” because it:
- Redesigns the incentive structure of knowledge production
- Creates value it cannot capture
- Invests in public goods
- Uses design as a scientific accelerant
- Commits to epistemic transparency
- Expands who gets to participate in science
- Challenges prestige economies
- Practices clarity at a structural level
Arcadia isn’t branding itself as brave. It is brave because it operates according to a different theory of what value is. This is real brand design!
VIII. Pattern Recognition
The pattern emerging from Arcadia:
- They create more value than they capture.
- They redesign incentives rather than accept them.
- They use design as infrastructure.
- They treat knowledge as a fluid, not an asset class.
- They optimize for the ecosystem, not the quarter.
- They reduce harm by accelerating future understanding.
- They operate according to principles, not optics.
These seven patterns will later unite all five companies.
OPENBIOME
Access, Market Failures, and the Economics of Stewardship
If Arcadia Science responds to an epistemic failure in how knowledge flows, OpenBiome responds to a structural failure in how medicine reaches people. Its existence is the result of a market failure so fundamental that most of biotech engineering cannot proceed without confronting it:
There are diseases where treatment exists, but the economic system does not deliver it.
OpenBiome’s founding question is one of the most courageous in modern public health:
“What if the barrier to life-saving therapy isn’t science, but logistics, economics, and access?”
To understand why this is brave, we need to understand:
- the history of fecal microbiota transplantation (FMT)
- the economics of last-mile access
- the systemwide cost burdens of C. difficile infection
- why no commercial actor stepped in
- how OpenBiome built a public-health supply chain in response
- and why OpenBiome’s model represents a distinct form of value creation that markets cannot price
I. The Historical Context: When Science Outpaces Systems
By the early 2000s, fecal microbiota transplantation, replacing disrupted gut microbiomes with stool from healthy donors, was known to be shockingly effective for recurrent Clostridioides difficile infections (one of the costliest and deadliest hospital-associated infections in the U.S.).
Clinical studies showed response rates often above 85%. Some studies approached 90–95%. This is unheard-of efficacy for a condition that causes:
- 500,000+ infections annually in the U.S.
- 29,000+ deaths
- $1–$4 billion in healthcare costs per year
FMT was a nearly perfect therapy for a narrow but devastating disease. And yet—It wasn’t reaching patients. Why? Because no one had built:
- supply chains
- donor-screening pipelines
- safety protocols
- standardized preparation methods
- shipping logistics
- hospital integration frameworks
In other words: Biology had a solution. The system did not.
II. The Founding of OpenBiome: Solving a Market Failure
OpenBiome emerged from two graduate students at MIT and Harvard who noticed a tragedy hiding in plain sight:
Patients were dying not because the therapy didn’t work, but because no one was responsible for getting it to them safely.
FMT requires:
- universal donor screening
- standardized processing
- cold-chain logistics
- clinician education
- safety surveillance
- regulatory compliance
- post-procedural monitoring
This is infrastructure, not innovation. In traditional market theory, infrastructure is a public good:
- non-rivalrous
- underfunded
- required for private innovation to succeed
But FMT had a further complication: It was not patentable. It was not easily commodified. It did not fit traditional venture economics. The therapy had enormous public benefit and near-zero capturable private value. This is the definition of a market failure.
OpenBiome was created to fix that failure, not through a profit motive, but through a stewardship motive.
III. OpenBiome’s Model: A Public-Health Supply Chain, Not a Company
OpenBiome built something most biotech companies never think to build:
- a donor recruitment + screening pipeline more rigorous than blood banks
- a GMP-like processing environment for stool
- logistics systems that allowed safe shipment to hospitals across the country
- clinical support structures for physicians unfamiliar with the therapy
- a safety monitoring system
- publications, education, and transparency initiatives
- global collaborations for microbiome access
They turned a niche therapy into an operationally viable, clinically scalable, ethically governed treatment system. This is not commercial innovation. This is public health engineering.
OpenBiome turned stool, a biological waste, into a governed, standardized medical resource through:
- multi-stage donor screening
- virology testing
- metabolomic profiling
- chain-of-custody documentation
- batch-level traceability
- clinician training modules
This is the biomedical equivalent of building a water-treatment plant. It ensures purity, safety, access, and public benefit. Markets rarely build water-treatment plants. Governance, ethics, and mission do.
IV. Economic Theory in Application
OpenBiome is a masterclass in applied health economics. Let’s decode their model through four economic lenses.
1. Market Failure Theory (Pigou, Stiglitz)
OpenBiome exists because:
- the treatment was low-margin
- the cost of infrastructure was high
- no IP moat existed
- no profit-maximizing actor had incentive to build the supply chain
Commercial actors avoid low-capture, high-public-benefit spaces. This is not moral failure, it is a structural feature of markets. So OpenBiome filled the gap. This is textbook “public good provision.”
2. Positive Externalities (Arrow, Romer)
OpenBiome’s work creates:
- lower recurrence rates of C. diff
- dramatically reduced healthcare costs
- decreased hospital readmissions
- reduced antibiotic resistance pressure
- system-level savings
But they cannot capture these financial gains. This is pure positive externality creation, and it is brave to build something whose value flows primarily to others.
3. Access Economics (Amartya Sen)
Sen’s capability framework says:
Health is not merely the absence of illness; it is the capability to live a life one values.
OpenBiome expands capability:
- patients regain health faster
- families avoid catastrophic costs
- hospitals reduce systemic strain
- clinicians gain reliable tools
Access is not charity. Access is value creation.
4. Trust Economics (Akerlof, Arrow)
OpenBiome built credibility not through hype, but through:
- transparency
- methodological rigor
- conservative communication
- ethical clarity
- consistency of quality
- public data
Trust reduces systemic friction. OpenBiome stabilizes the entire microbiome ecosystem simply by behaving with integrity. Trust is infrastructure.
V. Ethical and Societal Implications
OpenBiome’s model isn’t just economically important. It carries deep ethical weight.
OpenBiome stands for:
- equity in access
- scientific responsibility
- stewardship over exploitation
- public benefit over proprietary gain
- patient-first decision frameworks
In a landscape where biotech is often criticized for high prices, opaque motives, or exploitation of vulnerability, OpenBiome is a counter-narrative:
A biotech model built on care rather than capture.
VI. Design as Operational Ethics
Design is woven into everything OpenBiome does:
- patient information written in plain language
- clinician protocols designed for ease of adoption
- logistical workflows mapped for reliability
- safety dashboards for transparency
- publications that emphasize clarity
- a brand that signals humility, not hype
This is not identity design. This is systems design. OpenBiome’s design decisions tell us:
“We are here to serve. We are here to protect. We are here to make the therapy work for everyone.” This is design that shapes human behavior, safety, and access.
VII. Tensions, Limitations, and the Challenge of Being “Noncommercial”
Being a public-good provider in a commercial landscape creates tension:
- financial volatility
- philanthropic dependence
- lack of market incentives
- regulatory uncertainty
- competition with for-profit microbiome companies
- political vulnerability
- structural fragility
But this fragility is structural, not organizational.
It reflects the misalignment between:
- where value is created
- and where value is captured
OpenBiome lives in the gap. This is what makes them brave.
VIII. Pattern Recognition (OpenBiome’s Place in the Brave Brand Taxonomy)
OpenBiome reinforces the same patterns emerging from Arcadia:
- They create value the market cannot price.
- They reduce harm across population scales.
- They build infrastructure, not narratives.
- They treat design as governance.
- They absorb externalities the market would otherwise push onto patients.
- They engineer trust, not hype.
- They demonstrate that real biotech value is the reduction of future harm.
- They are mission-first in a system optimized for capital-first.
OpenBiome is bravery in the language of public health.
GINKGO BIOWORKS
Programming Life, Platform Economics, and the Value Architecture of Synthetic Biology
Ginkgo Bioworks is one of the most ambitious attempts in history to build a biological platform company — not a single-asset biotech, not a modality shop, not a pipeline machine, but an infrastructure layer for the bioeconomy.
To understand Ginkgo’s ambition, one has to understand the intellectual lineage behind it — a lineage stretching back through iGEM, MIT synthetic biology labs, the engineering ethos of standardization, and the economic logic of platforms like AWS (yes, I’m talking about the cloud).
Ginkgo is not simply a company.
Ginkgo is a theory of how biology should work.
It is also one of the clearest examples of how biotechnology creates, and misprices, value.
This is an attempt to tell the full story.
I. Origins: iGEM, Synthetic Biology, and the Dream of Biological Standardization
Ginkgo’s origin story begins before its founding — in the early 2000s, when synthetic biology was transitioning from a scientific curiosity into an engineering discipline.
A. iGEM: The Seedbed of Synthetic Biology Culture
iGEM (International Genetically Engineered Machine competition) was founded in 2003 at MIT. It was a radical experiment:
- standardize biological parts (“BioBricks”)
- teach undergraduates to engineer living systems
- create open-source registries
- democratize biological engineering
- cultivate an engineering mindset, not an academic one
Several future Ginkgo founders (Reshma Shetty, Austin Che, Barry Canton, Tom Knight, Jason Kelly) were deeply involved in this world. They were not just participants, they were architects of this emerging epistemology:
Life can be designed.
Life can be programmed.
Life can be standardized.
These ideas were not settled science. They were provocations, grounded in hope and abstraction but not yet in economic or industrial reality. Ginkgo was founded as the company that would attempt to materialize this belief.
II. Founding Logic: Biology Should Look Like Engineering
Ginkgo’s founding insight was not just scientific — it was economic:
Biology becomes exponentially more powerful when its components become programmable, modular, and reusable.
Which leads to:
- Cost of engineering biology will fall with automation and scale.
- Standardization increases reuse.
- Reuse increases innovation density.
- A “platform” can capture value across many verticals.
- An ecosystem will form around whoever builds this platform first.
This logic is deeply informed by engineering history:
- the semiconductor revolution
- cloud computing (AWS)
- modular software frameworks
- industrial automation
- platform economics (Metcalfe’s law, increasing returns)
Ginkgo’s thesis:
Biology is the next infrastructure category.
And they wanted to be the AWS of biology. Dang, that’s cool.
III. The Platform: Foundries, Codes, and Modular Biology
Ginkgo’s “foundry” is the physical manifestation of the dream:
- robots
- liquid handlers
- high-throughput screens
- automated analytics
- SciDB infrastructure
- cloud-scale data storage
- machine learning systems
- iterative design cycles
The goal is simple but massive:
Reduce the marginal cost of designing a biological function. Drive it toward zero.
This mirrors the AWS playbook:
- AWS reduced the cost of computing for startups.
- Ginkgo aims to reduce the cost of engineering biology for innovators.
When AWS lowered the cost of computing:
- new companies emerged
- innovation exploded
- venture funding accelerated
- digital infrastructure shifted dramatically
Ginkgo hopes to create the same phenomenon, but in the biological domain.
This is the platform imagination.
IV. Platform Economics: Increasing Returns, Ecosystem Strategy, and Network Effects
Now we go deeper into the economics behind Ginkgo’s platform ambition.
1. Increasing Returns to Scale
Most biotech companies face diminishing returns:
- each new drug costs more
- each experiment is bespoke
- each program has linear scaling
Platform companies are different:
- data compounds
- automation increases throughput
- standardized workflows reduce marginal cost
- design-build-test cycles compress
- past work accelerates future work
This is increasing returns to scale (the holy grail of platform economics).
2. Ecosystem Formation and Complementary Innovation
Ginkgo wants an ecosystem where:
- customers build on its platform
- partners integrate capabilities
- developers reuse biological “functions”
- a marketplace emerges
- third parties innovate faster because the infrastructure exists
Think:
- iOS App Store
- AWS marketplace
- semiconductor fabs
- cloud APIs
This is complementarity, one of the strongest forms of economic defensibility.
If Ginkgo succeeds, its value is not in contracts. Its value is in the ecosystem it enables.
3. The Biology API
This is the most visionary part, IMHO.
Ginkgo wants biology to have “endpoints”:
- “produce this molecule”
- “express this pathway”
- “tune this enzyme”
Where developers don’t need to know:
- strain engineering
- plasmid design
- metabolic balancing
- optimization techniques
- growth conditions
In this dream:
Biology becomes callable.
Biology becomes composable.
Biology becomes a service layer.
This is not metaphoric branding.
This is the architectural goal.
V. Narrative + Design: How Ginkgo Communicates a New Epistemology
Ginkgo’s narrative choices are deliberate:
- “make biology easier to engineer”
- “the organism company”
- “cell programming”
These are not just metaphors.
They are epistemic commitments:
- clarity over complexity
- analogy over obfuscation
- accessibility over gatekeeping
- engineering mindset over academic mystique
Ginkgo uses:
- bright imagery
- modular design
- playful visuals
- accessible writing
- approachable metaphors
This is not childish branding.
This is translation design, making a new domain understandable to non-experts.
This is how ecosystems are built:
- clarity
- invitation
- accessibility
You cannot build a platform with opacity.
VI. Historical Parallels: Bell Labs, Genentech, AWS
Ginkgo’s ambition echoes the great institutions of technological transformation.
Bell Labs:
Scientific infrastructure at scale. Innovation via shared knowledge, tools, and culture.
Genentech (early era):
Industrializing recombinant DNA. Turning discovery into a repeatable engineering discipline.
AWS:
Taking a costly, complex technical burden and turning it into a platform that democratizes innovation.
Ginkgo positions itself as the Bell Labs + AWS of biology.
Whether they fully achieve this remains to be seen, but the ambition itself is instructive.
VII. Critiques, Challenges, and Public Market Tension
A brave case study must also explore tension. Ginkgo has faced:
- short seller reports
- revenue model skepticism
- complexity of communicating platform value
- SPAC-era volatility
- difficulty explaining long-term economics to quarterly markets
- questions about scale and sustainability
These critiques are not signs of fraud or failure.
They are signs of misaligned time horizons:
- The market wants near-term cash flow.
- Ginkgo is building multi-decade infrastructure.
This is the platform paradox:
Infrastructure takes time.
Markets do not reward time.
AWS lost money for years.
Bell Labs was subsidized by a monopoly.
Semiconductor fabs required massive state support.
Bioplatforms face the same dilemma.
This is structural, not individual.
VIII. Economic Implications: Ginkgo as an Engine of Spillover Value
Here is the economic heart of the Ginkgo story:
If biology becomes programmable, the entire cost structure of biotech collapses downward. And innovation explodes outward.
Ginkgo’s value is not primarily in the products it touches.
It is in the reduction of future harm through:
- faster development cycles
- cheaper engineering
- more accessible innovation
- better global biodefense
- more resilient supply chains
- reduced environmental impact
- distributed creativity
Ginkgo is a bet on the meta-economy of biology, not the micro-economy of a single drug.
IX. Ethical + Societal Implications
Ginkgo’s work forces questions about:
- biosecurity
- dual-use technology
- power concentration
- global equity
- programmable life as a cultural shift
A platform with such reach requires:
- transparency
- governance
- ethical guardrails
- partnerships
- cultural stewardship
Brave companies must design for responsibility at scale, not simply capability at scale.
X. Why Ginkgo Is a Brave Biotech Brand
Ginkgo qualifies as “brave” because it:
- builds infrastructure rather than optics
- moves against extractive short-term pressures
- creates value it cannot fully capture
- attempts to reshape the entire biology innovation system
- communicates clearly in a domain that rewards opacity
- standardizes complexity rather than mystifying it
- designs for future ecosystems, not present revenue
Ginkgo is not brave because it markets itself as bold. It is brave because it commits to a long-term vision that markets are structurally incapable of valuing properly (at least today).
XI. Pattern Recognition Across Arcadia + OpenBiome + Ginkgo
The same patterns emerge again:
- They create value markets cannot price.
- They prioritize the reduction of future harm.
- They build systems, not stories.
- They expand who can participate in biotech.
- They operate on multi-decade horizons.
- They redesign incentives rather than accept them.
- They treat brand as epistemic clarity, not aesthetic flourish.
Ginkgo is brave because it behaves as if the future is worth investing in, even when the present is not built to reward that investment.
RECURSION
The Search Engine of Biology, Industrialized Learning Loops, and the Economics of Scale in Drug Discovery
Recursion is difficult to categorize because it is not merely a biotech company, not merely an AI company, and not merely an automation company.
Recursion is an epistemic system.
It is attempting to:
- transform biology from wet intuition into searchable structure
- convert phenotypes into data
- convert data into maps
- convert maps into navigable discovery space
- convert discovery into repeatable engineering
- convert engineering into a platform economy
If Ginkgo represents “make biology programmable,” Recursion represents:
“make biology searchable.”
Both are platform plays, but Recursion’s platform is not built from DNA parts. It is built from data density, automation throughput, and AI-driven pattern recognition.
To understand Recursion’s ambition, we must examine:
- the history of AI in biology
- Recursion’s OS architecture
- the economic meaning of scaling data
- the engineering of phenomics
- the automation stack
- Recursion’s collaboration with NVIDIA
- tensions between technical complexity and public-market optics
- narrative + design as clarity mechanisms
- the ethical implications of industrial-scale biological inference
Let’s go deep.
I. Origins: From Rare Disease Screens to Industrialized Phenotypic Mapping
Recursion began with a simple-but-profound observation:
Cellular morphology encodes a vast amount of biological information.
If you can image it precisely, at scale, across conditions, perturbations, and genetic contexts, and if you can use machine learning to detect patterns humans cannot, you can turn phenotypes into a data universe.
Recursion started by applying this insight to rare disease:
- take patient-derived cells
- perturb them with CRISPR, compounds, or other interventions
- image them
- extract high-dimensional morphological “signatures”
- compare against signatures of disease
- identify rescuing compounds
This is phenotype-based drug discovery, but industrialized.
This is not new in concept (phenotypic screening predates target-based drug discovery), but Recursion brought something else:
Scale + Automation + Machine Learning
…the triumvirate missing from earlier phenotypic paradigms.
II. Recursion OS: A Multi-Layered Biological Operating System
Recursion describes its system as the Recursion Operating System.
This is not metaphor.
It is architecture.
Let’s break down its layers:
1. Wet Lab Automation Layer (The Factory)
Recursion uses:
- robotics
- liquid handling systems
- high-content imaging
- automated sample prep
- rigorous QC pipelines
- parallelized experimental workflows
This is the biological equivalent of an automated semiconductor fab.
2. Data Layer (The Map)
Recursion has generated trillions of cellular images and petabytes of phenotypic data:
- morphological embeddings
- perturbation signatures
- genetic interaction networks
- chemical fingerprints
Each new experiment increases resolution of the biological landscape.
This is Romer-style endogenous growth, past knowledge scaffolds future discovery.
3. ML + AI Layer (The Interpreter)
Recursion applies:
- deep convolutional networks
- self-supervised learning
- representation learning
- dimensionality reduction
- similarity search
- predictive modeling
The goal is not to explain biology, but to navigate it.
This is critical:
Recursion treats biology as a search space, not a known system.
4. Insight Layer (The Navigator)
Insights include:
- disease signatures
- chemical rescue predictions
- target-agnostic relationships
- hit identification
- pathway inference
Recursion’s OS does not need a priori hypotheses. It discovers relationships bottom-up.
5. Scale Layer (BioHive / NVIDIA Partnership)
Recursion acquired Valence Discovery and partnered with NVIDIA to build BioHive, one of the most powerful supercomputers in biotech.
This dramatically accelerates:
- model training
- pattern recognition
- search-speed
- candidate ranking
This positions Recursion not as a biotech company with AI, but as an AI company with a biological substrate.
III. Why Recursion Matters: Moving Biology From Hypothesis-Driven to Search-Driven
Traditional drug discovery is:
- slow
- expensive
- linear
- hypothesis-constrained
- limited by human cognitive bandwidth
Recursion proposes something else:
What if drug discovery is not a linear pipeline but a multidimensional search problem? This is a profound epistemic shift.
Old Model:
Find target → design molecule → validate.
Recursion Model:
Map biology → explore map → identify promising regions → select effective interventions → validate downstream.
Biology becomes navigable.
This reduces:
- time
- cost
- failure risk
- sunk R&D expense
And increases:
- discovery surface area
- optionality
- hypothesis diversity
- serendipity
- systemic understanding
This is economic transformation, not incremental improvement.
IV. Platform Economics: Why Scale Is Recursion’s Moat
Recursion is a platform company because:
1. Data Begets Data (Self-Reinforcing Loops)
More experiments → richer models.
Richer models → better experiments.
Better experiments → more insight → more investment → more data.
This is a classic increasing returns system.
2. Models Improve With Volume (Learning Curves)
Like language models, Recursion’s AI improves with:
- scale
- diversity
- noise reduction
- multi-context embeddings
This compounds advantage.
3. Infrastructure Raises Barriers to Entry
No small biotech can replicate:
- automated factories
- millions of experiments
- trillion-image datasets
- supercomputing infrastructure
- proprietary embeddings
Recursion’s moat is systemic, not proprietary.
4. Partnerships Expand Ecosystem Reach
Partnerships with:
- Bayer
- Roche/Genentech
- Takeda
- NIH collaborations
…allow Recursion to create a platform economy.
Much like AWS powers thousands of digital companies, Recursion aims to power biological discovery for many others.
V. Design + Narrative: Making the Invisible Legible
Recursion communicates through a clarity-first approach:
- “decode biology”
- “industrialize drug discovery”
- “maps of biology and chemistry”
These phrases are not fluff.
They are epistemic anchors.
Recursion’s design system emphasizes:
- line drawings
- maps
- circuits
- simplicity
- data visualizations
- clean typography
This is design functioning as:
- translation
- trust-building
- decomplexification
- cognitive offloading
Recursion must explain something novel: that AI can understand biology in ways humans cannot. Design becomes the bridge between skepticism and comprehension.
VI. Critiques, Tensions, and Public Market Perception
Recursion faces the same issue as Ginkgo: markets do not know how to price infrastructure.
Challenges include:
- public misunderstanding of AI in drug discovery
- lumping AI companies into hype cycles
- misalignment between long-term value and short-term revenue
- confusion about what “platform” means
- skepticism toward non-linear R&D paths
- perceived lack of traditional pipelines
- enormous capital expenditure requirements
- data complexity too high for traditional investors
These are not weaknesses of Recursion, they are weaknesses of market comprehension. Recursion is building something closer to Bell Labs than to a biotech startup. Markets rarely understand Bell Labs until decades later.
VII. Ethical and Societal Implications: Industrialized Inference and Biological Power
Recursion’s work raises significant questions:
- Who owns biological insight?
- What happens when biology becomes predictable?
- How do we govern industrialized discovery?
- Does AI-driven biology centralize or distribute power?
- How do we audit ML models for biological accuracy?
Brave companies do not avoid these questions. They build governance around them.
Recursion has consistently emphasized:
- transparency
- partnerships
- scientific publications
- public explanation
- ethical framing
This is design-as-stewardship.
VIII. Why Recursion Is a Brave Biotech Brand
Recursion’s bravery lies in:
- Redefining what drug discovery is
- Building infrastructure before outputs
- Investing in scale the market cannot see
- Communicating with unusual clarity
- Applying AI not as a buzzword but as architecture
- Navigating complexity with humility
- Operating on multi-decade horizons
- Creating a new category—search-based drug discovery
Recursion is not brave because it positions itself that way. It is brave because it is building something vastly larger than a pipeline. Recursion is building a new epistemology of life science.
IX. Pattern Recognition Across Arcadia + OpenBiome + Ginkgo + Recursion
The same patterns emerge:
- They redefine what counts as value.
- They create value long before they capture any of it.
- They reduce future harm.
- They invest in ecosystem benefit.
- They build systems rather than stories.
- They challenge the economic status quo.
- They require design to make their work legible.
- They allocate courage toward infrastructure, not optics.
Recursion is brave because it insists that biology can be industrialized without being dehumanized, that intelligence can reveal patterns we could never see, and that this will not replace scientists, but empower them.
VERVE THERAPEUTICS
Gene Editing, Lifetime Burden Reduction, and the Economics of a Once-and-Done Future
To understand Verve Therapeutics, one must understand the sheer scale of the problem they are trying to solve:
Cardiovascular disease is the leading cause of death in the world. It is responsible for 18+ million deaths annually. It is responsible for one-third of all global mortality. It costs economies trillions in direct and indirect burden.
And crucially:
Most of that burden is the result of chronic, lifelong exposure to risk, not sudden catastrophic events. Verve is attempting to interrupt the arithmetic of risk itself.
This makes Verve not merely a gene-editing company. Not merely a cardiology company. Not merely a precision medicine company. Verve is a population health economics experiment. A test case for whether biotechnology can shift the trajectory of disease at the population level, not just individual level.
To understand Verve, we must examine:
- the biology of atherosclerosis
- the economics of chronic disease
- the failure of payer incentives
- the architecture of once-and-done gene editing
- the ethical implications of irreversible interventions
- the design and narrative implications of describing such a therapy
- why this approach constitutes real value creation
- and why the market is poorly structured to reward it
Let’s go deep.
I. The Burden: Atherosclerotic Cardiovascular Disease as a Macro-Economic Problem
Atherosclerosis is not a single disease. It is a long-term process driven by:
- LDL cholesterol exposure
- inflammation
- metabolic health
- genetics
- environmental factors
It begins in childhood. It accelerates silently. It results (decades later) in:
- heart attacks
- strokes
- disability
- heart failure
- premature death
This means:
Cardiovascular disease is the compound interest of biological risk. Most therapies treat the outcomes, not the exposure curve. Statins and PCSK9 inhibitors reduce LDL cholesterol, but only while taken.
And most patients:
- do not adhere
- cannot afford
- experience side effects
- lack access
- or discontinue therapy
This is a structural failure, not a clinical one.
II. Intertemporal Economics: The Value of Lowering Lifetime LDL Exposure
Health economists model LDL exposure through an integrated metric:
Area Under the LDL Curve (AUC-LDL).
Lowering LDL earlier (and permanently) reduces:
- the slope of risk accumulation
- the probability of future catastrophic events
- overall healthcare burden
- lost productivity
- disability-adjusted life years (DALYs)
- direct medical expenditures
- indirect societal costs
Verve’s core insight is an economic one:
A one-time intervention early in life may have more value than decades of pharma products. This is real value creation, not value extraction. Markets, however, are not built to reward long-term benefit. Chronic therapies create revenue streams. Once-and-done cures eliminate them.
Which is why Verve is a brave company by definition.
III. Verve’s Science: Base Editing as Risk Rewriting
Verve uses in vivo base editing delivered via lipid nanoparticles (LNPs) to make a precise, permanent change to genes that regulate cholesterol metabolism.
Specifically: PCSK9
- reduces LDL receptor degradation
- increases LDL clearance
- safely lowers LDL cholesterol
- proven through human genetics (PCSK9 loss-of-function mutations reduce lifetime cardiac events)
This is one of the cleanest genetic targets in medicine:
- validated in nature
- validated in humans
- validated pharmacologically
- validated epidemiologically
Base editing allows:
- single nucleotide conversions
- without double-strand breaks
- which reduces genomic instability risks
- and increases safety for in vivo application
If successful:
Verve edits the risk, not the disease. This is public health intervention at the genetic level.
IV. Delivery Architecture: Why LNPs Matter
Lipid nanoparticles make in vivo editing possible by:
- targeting the liver (where cholesterol metabolism is regulated)
- protecting the editing machinery
- enabling controlled delivery
- allowing a one-time treatment
This is the same delivery technology used for mRNA vaccines, a massive validation of the modality at global scale. Thus, Verve sits at the intersection of:
- human genetics
- RNA therapeutics
- base editing
- nanomedicine
- population epidemiology
This is a very rare convergence.
V. The Economics of a Once-and-Done Intervention
Now we go deeper into the economic consequences.
1. Up-Front Cost vs Lifetime Savings
A one-time base-editing therapy may cost:
- $300K–$1M (modeled loosely on gene therapies)
But the lifetime cost of cardiovascular disease (direct + indirect) can exceed:
- $1.5–$2M per patient
- plus societal costs
- plus caregiver burden
- plus productivity losses
- plus hospital system strain
Economists call this Intertemporal Arbitrage—spend now to avoid catastrophic future costs.
2. Payer Incentives Misaligned
Here is the systemic challenge:
- insurers churn every 2–3 years
- patients move between payers
- payers do not capture long-term savings
- payers prefer costs pushed into the future
- once-and-done therapies create short-term loss, long-term gain
This is a tragedy of misaligned horizons. It is not Verve’s fault. It is the structure of U.S. health insurance. Medicare would benefit. Private payers often would not.
This is why brave companies face friction. They create value, not revenue.
3. DALYs, QALYs, and Value-Based Pricing
Health economists measure:
- DALYs (disability-adjusted life years)
- QALYs (quality-adjusted life years)
A once-and-done gene edit in a high-risk population could produce:
- decades of additional QALYs
- dramatic reductions in DALYs
- massive societal benefit
From a public perspective, Verve’s therapy is extremely likely to be cost-effective. From a payer perspective, The timing of benefit is inconvenient. This is the economic tension at the heart of innovation.
VI. Ethics: Irreversible Interventions and Collective Benefit
Verve’s therapy is:
- somatic
- non-heritable
- targeted
- reversible only in the sense of probabilistic harm reduction
It is ethically uncontroversial compared to germline editing, but it raises meaningful questions:
1. Do individuals fully understand irreversible edits?
Informed consent must be designed, not just delivered.
2. How should society prioritize access?
High-genetic-risk populations?
High-burden communities?
3. Should such therapies be subsidized or public-good funded?
Economists would argue yes.
4. What is the ethical obligation to intervene early?
If we can reduce harm for millions, should we?
Verve cannot answer these alone. But they are operating in a category where the ethical stakes mirror the scientific stakes.
VII. Narrative + Design: Making Permanence Legible
Verve’s brand is a study in:
- clarity
- simplicity
- humility
- precision
Their communication avoids:
- hype
- sensationalism
- genetic determinism
- fear-based messaging
Instead they use:
- clean diagrams
- straightforward explanations
- simple metaphors (“editing the gene that regulates cholesterol”)
- calm tones
- sober descriptions
This is design functioning as ethical grounding. When you tell the public you are editing genes inside the liver of a living human, design is not aesthetic. Design is governance.
VIII. Tensions, Limitations, and Future Challenges
Verve faces:
- uncertain regulatory pathways for base editing
- long-term safety measurement difficulty
- payer reluctance
- manufacturing scale-up challenges
- public misunderstanding of gene editing
- the need to prove durability and effectiveness over decades
This is expected. True innovation always exposes where the system is misaligned.
IX. Why Verve Is a Brave Biotech Brand
Verve is brave because it:
- targets the largest burden of disease in the world
- attempts to eliminate risk rather than manage symptoms
- creates long-term societal value over short-term revenue
- fights against payer incentives that discourage prevention
- communicates with precision and restraint
- applies the most advanced technologies to the most common diseases
- attempts to democratize gene editing beyond rare disease
- operates on a timeline markets cannot price correctly
Verve is not brave because it says so. Verve is brave because it builds according to a value system at odds with market incentives.
X. Pattern Recognition Across All Four (Arcadia + OpenBiome + Ginkgo + Recursion + Verve)
With Verve added, the pattern becomes unmistakable:
- They build infrastructure for the future, not products for the quarter.
- They reduce future harm at scale.
- They challenge the economics of healthcare and innovation.
- They bring design into the epistemic core of their work.
- They create value they cannot capture.
- They expand participation in science or health.
- They operate with ethical coherence.
- They resist extractive incentives.
- They make the invisible legible.
- They accelerate understanding across the ecosystem.
This is what “brave” biotech looks like.
4. The Shared Architecture of a Brave Biotech Brand
What Arcadia, OpenBiome, Ginkgo, Recursion, and Verve have in common
Looking across Arcadia, OpenBiome, Ginkgo, Recursion, and Verve, the similarities are not superficial. They share a deep structure, a common architecture of how they see value, time, risk, and responsibility. The patterns show up in nine dimensions:
4.1 They redefine what counts as value
None of these organizations accept the default definition of value as “revenue today” or “valuation at the next round.”
- Arcadia defines value as knowledge that moves—methods, tools, insights that other scientists can reuse.
- OpenBiome defines value as access—a safe, governed supply chain that turns an almost-free therapy into a reliable public resource.
- Ginkgo defines value as capability—the ability of others to program biology without rebuilding infrastructure from scratch.
- Recursion defines value as understanding—maps that make the biological search space navigable.
- Verve defines value as burden eliminated—decades of future cardiac events and suffering that never materialize.
Underneath all of this sits a simple, sharp insight:
Biotech creates value in a fundamentally different way than most industries. The unit of value is not the product. It is the reduction of future harm. And markets are not set up to price that correctly.
That mispricing is the central problem; everything else follows from it.
4.2 They create more value than they can capture
Each of these organizations is a net exporter of value:
- Arcadia’s publishing model accelerates others’ research.
- OpenBiome’s infrastructure lowers healthcare system costs.
- Ginkgo’s platform makes entire categories of companies possible.
- Recursion’s OS raises the baseline of what is knowable in biology.
- Verve’s success would erase future revenue streams for multiple chronic therapies.
They are all, in different ways, subsidizing the future. From a narrow financial lens, this looks irrational. From a broader economic lens, it is exactly what real value creation looks like: non-rivalrous, spillover-rich, compounding at the level of ecosystems, not quarters.
4.3 They operate on longer time horizons
All five entities make decisions that only make sense on decade-scale horizons:
- Arcadia is rebuilding publishing norms.
- OpenBiome is changing standards for microbiome access and safety.
- Ginkgo is betting on a full-stack bioeconomy that may take decades to mature.
- Recursion is building learning curves that become powerful only with scale and time.
- Verve is intervening in disease processes that unfold over a lifetime.
Short-term optimization would kill any of these initiatives. They are only coherent if one believes the future is real and worth investing in.
4.4 They design for positive externalities
Each organization is structured to maximize benefits that spill beyond its own P&L:
- Arcadia optimizes for reusable knowledge.
- OpenBiome optimizes for reduced system burden.
- Ginkgo optimizes for complementary innovation.
- Recursion optimizes for compounding insight.
- Verve optimizes for reduced population-level harm.
They are, in effect, externality engines, designed to push good into the system even where it can’t be billed.
4.5 They reduce information asymmetry and cognitive load
All five companies confront the same reality: biotech is an extreme information asymmetry environment. Their response is to design for comprehension:
- Arcadia’s pubs read like modular product docs.
- OpenBiome’s protocols and communications prioritize plain language and safety.
- Ginkgo uses clean metaphors (“programming biology”) and playful design to disarm complexity.
- Recursion uses maps and simple language (“decode biology to industrialize drug discovery”) to articulate an alien epistemology.
- Verve communicates permanent gene editing with precision and calm restraint.
Brand, in each case, functions as a trust interface. It reduces cognitive burden. It helps people understand what is actually happening.
4.6 They treat design as epistemology, not ornament
Design choices are never just cosmetic:
- Arcadia’s design system encodes a belief in transparency and iterative knowledge.
- OpenBiome’s operational design encodes a belief in stewardship and patient safety.
- Ginkgo’s visuals and language encode a belief that biology should feel approachable and modular.
- Recursion’s interface and narrative encode a belief that biology can be mapped and navigated.
- Verve’s visual and verbal restraint encodes a belief in humility around high-stakes editing.
In all cases, design is not an afterthought; it is how their theory of value becomes real.
4.7 They challenge existing incentive structures
Each organization has to push against an existing incentive landscape:
- Arcadia pushes against prestige publishing and paywalled journals.
- OpenBiome pushes against the absence of commercial incentive for FMT infrastructure.
- Ginkgo pushes against short-term public market expectations and misunderstanding of platforms.
- Recursion pushes against pipeline-centric evaluation of biotech and AI hype fatigue.
- Verve pushes against payer horizons that undervalue prevention and once-and-done therapies.
Bravery here is not rhetoric; it is the willingness to build in misaligned conditions.
4.8 They behave as future ancestors
There is also a quieter pattern: each company behaves as if it will be judged not just by investors, but by future generations.
- Will they be remembered for accelerating understanding?
- For making therapy accessible?
- For democratizing tools?
- For reducing population-level harm?
- For treating biology with clarity and care?
That imagined future gaze shapes present decisions. It is a form of long-term moral accounting that sits underneath the spreadsheets.
4.9 They make the invisible visible
Finally, all five companies specialize in surfacing what is otherwise invisible:
- Arcadia: invisible early-stage work and methods
- OpenBiome: invisible logistical, safety, and governance labor
- Ginkgo: invisible infrastructure that makes others possible
- Recursion: invisible structure in high-dimensional biology
- Verve: invisible lifetime risk curves and their modification
This, ultimately, is what brave biotech brands do: they bring hidden value into view, and argue for building around it.
Why It’s So Hard to Build This Way
The structural headwinds brave biotech brands face
If this model of biotech is so clearly better, for patients, for science, for society, then why isn’t everyone building this way? Because the existing system exerts pressure in the opposite direction. Bravery in biotech is not about personality. It is about resisting structural forces that reward extraction and short-termism.
A few of the key headwinds:
5.1 Venture timelines vs. biological timelines
Most venture cycles expect:
- clear traction in 3–5 years
- exit potential in 7–10
- a narrative that gets sharper every round
Biology does not care.
- ecosystems take decades to build
- prevention benefits surface late
- infrastructure returns accumulate slowly
- trust is fragile and non-linear
Founders building like Arcadia, OpenBiome, Ginkgo, Recursion, or Verve are borrowing against time the market does not want to lend.
5.2 Payer incentives and misaligned horizons
Healthcare payers churn membership. The entity paying for an intervention today might not reap the savings 10–20 years from now.
Result:
- chronic, recurring revenue streams are structurally favored
- once-and-done interventions are structurally resisted
- prevention is underfunded relative to treatment
Verve runs directly into this. So will anyone working on long-term disease modification, early intervention, or environmental health.
5.3 IP regimes that reward enclosure
Patent structures and exclusivity periods can incentivize:
- maximal capture of rents
- defensive IP hoarding
- enclosure of basic tools
- litigation over collaboration
Arcadia’s openness, OpenBiome’s stewardship of common resources, and Ginkgo’s platform stance all swim upstream from this logic.
5.4 Information asymmetry and hype cycles
Because biotech is complex and opaque, stories that:
- oversimplify
- exaggerate
- selectively disclose
- frame speculative ideas as inevitabilities
are often rewarded in the short term.
This creates cyclical mistrust:
- hype → crash → public skepticism → regulatory overcorrection
Brave brands have to hold the line on humility and clarity in a market that often rewards the opposite.
5.5 The cost of being first
Infrastructure players incur:
- up-front capex
- cultural risk
- narrative confusion
- category education burden
Arcadia, OpenBiome, Ginkgo, Recursion, and Verve each had to spend enormous energy just to explain what they are. Pioneers don’t just pay in dollars; they pay in explanation.
6. Brand and Design as Economic Infrastructure
Not a wrapper, but a corrective mechanism
In this context, brand and design are not about polish. They are about survival. They serve four economic functions that become especially critical in biotech:
6.1 Reducing information asymmetry
Clear, honest, well-structured communication:
- helps investors understand what they are funding
- helps regulators assess risk and intent
- helps patients and the public make sense of high-stakes decisions
- helps partners evaluate fit and potential
This reduces:
- perceived risk
- volatility
- regulatory friction
- rumor and speculation
- mispriced fear
Brand is the public expression of a company’s theory of value in language others can actually use.
6.2 Aligning internal decision-making
A strong, coherent brand architecture:
- clarifies who the company is for
- clarifies what it is optimizing for
- clarifies which trade-offs it will not make
- creates a shared narrative for teams to act from
This reduces:
- coordination cost
- internal politics
- mission drift
- strategic whiplash
Brand is internal infrastructure before it is external signal.
6.3 Making intangible assets legible
Trust, reputation, clarity, coherence, and ethical behavior are intangible assets that drive real enterprise value.
Design and narrative are how those intangibles become tangible enough to:
- show up in investor confidence
- impact valuation
- influence recruitment
- shape partnership dynamics
- build long-term goodwill
In this sense, brand is an accounting tool for the things spreadsheets cannot see easily.
6.4 Embedding values into systems
Design decisions are the practical articulation of values:
- What do you publish?
- How do you show uncertainty?
- How easy is it to find risk information?
- How do you describe who will and will not benefit?
- How do you visually represent control, consent, and care?
When done well, brand and design ensure that values are not just written on a slide, but infused into every touchpoint and operationalized.
7. What This Demands in Practice
A practical lens for founders and teams
A theory is only useful if it can be acted upon. For founders and leaders who want to build a brave biotech brand, one that actually creates value instead of just capturing it, this framework implies a set of concrete commitments. They are demanding, but they are also clarifying.
7.1 Articulate your theory of value
Not: “We make X for Y.”
But:
- What kind of harm are we reducing, and on what time horizon?
- Which externalities are we willing to own?
- What public goods are we contributing to (knowledge, access, capability)?
- How do we think about value beyond share price: in lives, futures, and ecosystems?
Write this down. Test it. Let it inform everything.
Decide who your stakeholders really are
List them explicitly:
- patients
- caregivers
- clinicians
- communities
- regulators
- future generations
- ecosystems
- employees
- investors
Then ask:
- What does value look like for each of them?
- Where are their interests aligned, and where are they not?
- What will we optimize for when trade-offs are unavoidable?
Brave brands do not pretend there are no trade-offs. They name them and design around them.
Design for transparency by default
Build systems that assume:
- someone will read the protocol
- someone will scrutinize the data
- someone will remember what you claimed
This means:
- clear documentation
- legible publications
- honest limitation sections
- realistic timelines
- careful positioning of risk vs benefit
Transparency is cheaper to design in than to retrofit under pressure.
7.4 Invest in design and narrative as core infrastructure
Not as a coat of paint. As:
- translation
- coordination
- governance
- trust-building
- long-term absorption of complexity
This may look like:
- dedicated time with design and brand partners early
- clear principles for how uncertainty is communicated
- consistent metaphors and models for explaining the work
- visual systems that reduce anxiety rather than amplify hype
7.5 Commit to building more value than you capture
This is the heart of bravery. It does not mean ignoring financial discipline. It means structuring the company so that:
- ecosystems are healthier because you exist
- knowledge moves faster because you exist
- access is fairer because you exist
- future harm is lower because you exist
And then telling that story concretely, not abstractly.
An Incomplete Manifesto for the Brave Biotech Brand
A brave biotech brand understands that the unit of value is not the product. It is the reduction of future harm.
A brave biotech brand refuses to confuse valuation with contribution.
It creates more value than it can capture. In knowledge. In access. In capability. In trust.
It builds infrastructure, not just headlines. Ecosystems, not just exits.
It treats design as leadership:
as the way complexity becomes clarity,
as the way values become behavior,
as the way behavior becomes trust.
It speaks plainly in a field that rewards obscurity.
It shows its work.
It owns its uncertainty.
It publishes more than its victories.
It does not outsource ethics.
It internalizes externalities.
It imagines future generations,
looking back and asking,
“Did you leave the world with less suffering than you found it?”
A brave biotech brand is not afraid of slowness
when slowness is what safety demands.
It is not afraid of openness
when openness is what progress demands.
It does not exist to extract from illness.
It exists to shorten the distance
between what we know is possible
and the lives we actually live.
In an economy that misprices what matters most,
a brave biotech brand is a decision
to build as if the future is real,
and as if we owe that future something more
than the maximum returns the present can tolerate.
Sources & Further Reading
A curated selection of the thinkers, research, and scientific foundations that informed this piece.
I. Economics of Value, Public Goods, and Innovation
Mariana Mazzucato — The Value of Everything (2018)
Defines the modern distinction between value creation vs. value extraction. A foundational lens for understanding mispriced value in biotech.
Kenneth Arrow — “Economic Welfare and the Allocation of Resources for Invention” (1962)
The seminal work establishing knowledge as a public good and explaining why markets underfund innovation.
Joseph Stiglitz — “The Contributions of the Economics of Information” (2000)
Outlines how asymmetry shapes markets, particularly where expertise gaps are high.
George Akerlof — “The Market for Lemons” (1970)
A model of trust-based market failure central to understanding biotech communication challenges.
Paul Romer — “Endogenous Technological Change” (1990)
Formalizes knowledge growth, spillovers, and innovation ecosystems.
Robert (Bob) Allen & Brian Arthur — Increasing Returns and Path Dependence
Key frameworks for understanding why platforms (like Ginkgo and Recursion) create compounding value.
Elinor Ostrom — Governing the Commons (1990)
Brilliant insights on shared-resource governance, relevant for open science, communal datasets, and scientific infrastructure.
Amartya Sen — Development as Freedom (1999)
A broader ethical-economic lens on capability, access, and long-run human benefit.
II. Biotech Case Studies & Organizational Models
Arcadia Science
- arcadiascience.com
- Arcadia Publishing Model documentation
For their open-science publishing system and organizational transparency.
OpenBiome
- openbiome.org
- CDC & NIH FMT safety statements
For clinical and economic impact of microbiome interventions and non-profit biotech models.
Ginkgo Bioworks
- ginkgobioworks.com
- iGEM historical documents (igem.org)
- Ginkgo investor materials
Foundational for platform economics, engineering biology at scale, and the Fab/Farm analogy.
Recursion
- recursion.com
- NVIDIA + Recursion BioHive partnership material
- High-content imaging & Cell Painting assay literature (Bray et al., 2016)
Demonstrating AI phenomics, industrialized experimentation, and OS architectures for biology.
Verve Therapeutics
- vervetx.com
- PCSK9 genetic studies (Cohen et al., NEJM)
- Base editing literature (Komor et al., Nature 2016)
For the intersection of human genetics, editing precision, and population-level value creation.
III. Scientific & Epidemiological Foundations
CDC — C. diff Infections (Annual Reports)
Establishes burden of disease and underscores the societal value of OpenBiome’s work.
WHO — Global Cardiovascular Disease Statistics
Key for contextualizing Verve’s long-horizon prevention models.
NEJM & Nature — PCSK9 and Lifetime LDL Exposure
Studies by Cohen, Hobbs, and others forming the basis of the AUC-LDL reduction model.
Base Editing — Komor et al., “Programmable Editing of a Target Base in Genomic DNA” (Nature, 2016)
Foundational paper for the engineering frameworks referenced in the Verve section.
Bruce Mau — Massive Change + MC24
Design as systems leadership and an operating philosophy rather than aesthetics.
Herbert Simon — The Sciences of the Artificial
Foundational thinking on design as decision-making architecture.
Donella Meadows — Thinking in Systems
Systems behavior, leverage points, and complexity—directly relevant to biotech’s design of futures.
IDEO & Human-Centered Design Resources
On design’s role in navigating complexity, trust, and communication.
V. Platforms, Infrastructure, and Technology Analogies
AWS (Amazon Annual Letters, 2003–2010)
Origins of platform infrastructure and utility computing, informing comparisons to Ginkgo and Recursion.
BioBricks Foundation & Tom Knight
Early writings on modular, standardized biological parts—historical roots of the synthetic biology platform mindset.
DARPA Biological Technologies Office
A living example of platform-first thinking for biological systems.
Human Genome Project Documentation (NIH)
A public-goods triumph that continues to shape modern biotech externalities.
VI. Additional Context & Intellectual Lineage
These works inform the philosophical and ethical orientation of this article:
Michael Sandel — What Money Can’t Buy
On moral limits of markets.
Rebecca Henderson — Reimagining Capitalism
On aligning business with long-term societal value.
Anne Case & Angus Deaton — Deaths of Despair
Context for the real stakes of biotech beyond valuation.
Carl Bergstrom & Jevin West — Calling Bullshit
On clarity, epistemic rigor, and trust—critical for scientific communication.